N-benzyl-3-(1H-imidazol-1-yl)propan-1-amine | 112086-52-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-benzyl-3-(1H-imidazol-1-yl)propan-1-amine
• 英文别名: 3-(1H-imidazol-1-yl)propyl-phenylmethylamine；benzyl(3-imidazol-1-yl-propyl)amine；Benzyl-(3-imidazol-1-yl-propyl)-amine；N-benzyl-3-imidazol-1-ylpropan-1-amine
• CAS: 112086-52-9
• 化学式: C₁₃H₁₇N₃
• mdl: MFCD04579041
• 分子量: 215.298
• InChiKey: PUHMXLKXQDOCFC-UHFFFAOYSA-N

物化性质

• 沸点：
  399.3±25.0 °C(Predicted)
• 密度：
  1.04±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.307
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  2-(Toluene-4-sulfonylamino)-benzoyl chloride 、 N-benzyl-3-(1H-imidazol-1-yl)propan-1-amine 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-Benzyl-N-(3-imidazol-1-yl-propyl)-2-(toluene-4-sulfonylamino)-benzamide
  参考文献：
  名称：

  Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel

  摘要：

  The search for novel, potent Kv1.5 blockers based on an anthranilic amide scaffold employing a pharmacophore-based virtual screening approach is described. The synthesis and structure-activity relationships (SAR) with respect to inhibition of the Kv1.5 channel are discussed. The most potent compounds display sub-micromolar inhibition of Kv1.5 and no significant effect on the HERG channel. In addition, good oral bioavailability is demonstrated for compound X in rats. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.03.057
• 作为产物：
  描述：

  N-benzylidene-3-(1H-imidazo-1-lyl)-1-propaneamine 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成 N-benzyl-3-(1H-imidazol-1-yl)propan-1-amine
  参考文献：
  名称：

  合成新型不对称取代仲胺的可扩展方法

  摘要：

  探索了快速，简便，可扩展的方法，用于通过还原胺化合成包含萘，吲哚，吡啶和咪唑部分的不对称取代的仲胺。所研究的操作程序在50至30 mmol的规模上是成功的，并且具有扩大规模的巨大潜力。

  DOI：

  10.2298/jsc110408173r

文献信息

• Discovery of Novel Acetamide-Based Heme Oxygenase-1 Inhibitors with Potent <i>In Vitro</i> Antiproliferative Activity
  作者：Antonino N. Fallica、Valeria Sorrenti、Agata G. D’Amico、Loredana Salerno、Giuseppe Romeo、Sebastiano Intagliata、Valeria Consoli、Giuseppe Floresta、Antonio Rescifina、Velia D’Agata、Luca Vanella、Valeria Pittalà

  DOI：10.1021/acs.jmedchem.1c00633

  日期：2021.9.23

  promotes heme catabolism exercising cytoprotective roles in normal and cancer cells. Herein, we report the design, synthesis, molecular modeling, and biological evaluation of novel HO-1 inhibitors. Specifically, an amide linker in the central spacer and an imidazole were fixed, and the hydrophobic moiety required by the pharmacophore was largely modified. In many tumors, overexpression of HO-1 correlates

  血红素加氧酶-1 (HO-1) 促进血红素分解代谢，在正常细胞和癌细胞中发挥细胞保护作用。在此，我们报告了新型 HO-1 抑制剂的设计、合成、分子建模和生物学评价。具体来说，固定了中心间隔基中的酰胺连接体和咪唑，并对药效团所需的疏水部分进行了很大程度的修饰。在许多肿瘤中，HO-1 的过度表达与不良预后和化疗耐药相关，表明抑制 HO-1 作为一种可能的抗肿瘤策略。因此，化合物7i和7l – p因其对抗 HO-1 的效力而出现，并研究了它们对前列腺 (DU145)、肺癌 (A549) 和胶质母细胞瘤 (U87MG、A172) 癌细胞的抗癌活性。所选化合物对 U87MG 细胞表现出最佳活性。进一步研究了化合物7l的细胞内酶HO-1活性、表达水平以及对细胞侵袭和血管内皮生长因子(VEGF)胞外释放的影响。获得的数据表明7l可以通过调节HO-1表达来降低细胞侵袭性。
• Anthranilamides and methods of their use
  申请人：——

  公开号：US20030187033A1

  公开（公告）日：2003-10-02

  The present invention is related to anthranilamides of formula I, 1 in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).

  本发明涉及具有式I的蒽酰胺，其中R(1)至R(7)具有本文中指示的含义，其制备方法，它们作为药物的用途，以及含有它们的药物制剂。这些化合物作用于Kv1.5钾通道，抑制一种被称为人类心房中超快速激活延迟整流器的钾电流。因此，这些化合物适用于作为新型抗心律失常药物，用于治疗和预防心房心律失常（例如心房颤动（AF）或心房扑动）。
• Anthranilamides with heteroarylsulfonyl side chain, process of preparation, and use
  申请人：——

  公开号：US20030114499A1

  公开（公告）日：2003-06-19

  This invention encompasses anthranilamides with heteroarylsulfonyl side chain, process for their preparation, their use as medicament or diagnostic aid, and pharmaceutical preparations containing them. Compounds of formula I, 1 in which R1 to R7 have the meanings stated in the claims, act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. They are therefore suitable as novel antiarrhythmic ingredients, such as for the treatment and prophylaxis of atrial arrhythmias, e.g. atrial fibrillation (AF) or atrial flutter.

  这项发明涵盖了具有杂环磺酰基侧链的蒽酰胺，其制备方法，它们作为药物或诊断辅助剂的用途，以及含有它们的制药制剂。具有式I的化合物，在其中R1至R7具有权利要求中所述的含义，作用于Kv1.5钾通道，并抑制被称为人类心房中超快速激活延迟整流器的钾电流。因此，它们适用作为新型抗心律失常成分，例如用于治疗和预防心房心律失常，如心房颤动（AF）或心房扑动。
• ANTHRANILAMIDES AND METHODS OF THEIR USE
  申请人：Brendel Joachim

  公开号：US20070117807A1

  公开（公告）日：2007-05-24

  The present invention is related to a process for preparing anthranilamides of formula I, in which R(1) to R(7) have the meanings indicated herein, a process for their preparation, their use as medicaments, and pharmaceutical preparations containing them. The compounds act on the Kv1.5 potassium channel and inhibit a potassium current which is referred to as the ultra-rapidly activating delayed rectifier in the atrium of the human heart. The compounds are therefore suitable for use as novel antiarrhythmic agents for the treatment and prophylaxis of atrial arrhythmias (e.g., atrial fibrillation (AF) or atrial flutter).

  本发明涉及一种制备式I的蒽酰胺的方法，其中R（1）至R（7）具有本文中所示的含义，其制备方法，作为药物的使用以及含有它们的制药制剂。该化合物对Kv1.5钾通道产生作用，并抑制被称为人类心房中超快速激活延迟整流器的钾电流。因此，该化合物适用于作为新型抗心律失常剂用于治疗和预防心房心律失常（例如心房颤动（AF）或心房扑动）。
• Inhibitors of farnesyl-protein transferase
  申请人：Schering Corporation

  公开号：US06432959B1

  公开（公告）日：2002-08-13

  Novel compounds and pharmaceutical compositions are disclosed which are inhibitors of the enzyme, farnesyl protein transferase. Also disclosed is a method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells. The method comprises administering the novel aminooxyamide compound to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammals such as a human.

  本发明揭示了一种抑制酶-法尼酰基转移酶的化合物和药物组合物。还揭示了一种抑制Ras功能从而抑制细胞异常生长的方法。该方法包括向生物系统中给予新的氨氧胺化合物。特别是，该方法抑制哺乳动物(如人类)中细胞的异常生长。